Dr. Reddy's Laboratories
227 hedge funds and large institutions have $1.79B invested in Dr. Reddy's Laboratories in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 97 increasing their positions, 56 reducing their positions, and 21 closing their positions.
99% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $508K
73% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 56
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
3% more funds holding
Funds holding: 221 → 227 (+6)
3% less capital invested
Capital invested by funds: $1.84B → $1.79B (-$49M)
2.04% less ownership
Funds ownership: 72.32% → 70.28% (-2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$17.1M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$14.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$9.71M |
| 4 |
BlackRock
New York
|
+$9.17M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$8.59M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$34.4M |
| 2 |
AIM
Aikya Investment Management
London,
United Kingdom
|
-$24.3M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$14.6M |
| 4 |
Millennium Management
New York
|
-$13.9M |
| 5 |
JP Morgan Chase
New York
|
-$11.1M |
RDY Hedge Fund Activity: Q3 2024 in Review
227 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q3 2024, worth a combined $1.79B — down 2.7% from $1.84B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RDY positions and 21 closed out — a net gain of 8 holders — while 97 added to existing stakes and 56 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $17.1M. The largest seller was Goldman Sachs, cutting an estimated $34.4M.
- 227 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q3 2024, up from 221 in Q2 2024.
- Funds reported $1.79B of Dr. Reddy's Laboratories stock for Q3 2024, down 2.7% quarter-over-quarter.
- 29 funds opened new Dr. Reddy's Laboratories positions in Q3 2024 and 21 closed out, a net change of +8 holders.
- The largest Dr. Reddy's Laboratories buyer in Q3 2024 was Morgan Stanley, an estimated $17.1M added.
- The largest Dr. Reddy's Laboratories seller in Q3 2024 was Goldman Sachs, an estimated $34.4M sold.
Based on aggregated 13F filings for Q3 2024.